NUVELO, INC. INDENTUREIndenture • July 8th, 2003 • Nuvelo Inc • In vitro & in vivo diagnostic substances • New York
N-MER, INC.Option Agreement • April 1st, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
BY AND AMONG HYSEQ, INC.,Merger Agreement • November 12th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • Delaware
HYSEQ, INC.Underwriting Agreement • July 17th, 1997 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
EXHIBIT 4.9 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of November 13, 2001, among Hyseq, Inc., a Nevada corporation (the "Company"), and Affymetrix, Inc. a Delaware corporation (the...Registration Rights Agreement • April 1st, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
Hyseq, Inc. andRights Agreement • July 31st, 1998 • Hyseq Inc • In vitro & in vivo diagnostic substances • Nevada
EXHIBIT 4.6 RIGHTS AGREEMENT AMENDMENT This Amendment, dated as of November 9, 2002, to the Rights Agreement, dated as of June 5, 1998 (the "Rights Agreement"), is between Hyseq, Inc., a Nevada corporation (the "Company"), and U.S. Stock Transfer...Rights Agreement • November 27th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • Delaware
RECITALSTermination Agreement • August 14th, 2003 • Nuvelo Inc • In vitro & in vivo diagnostic substances • California
EXHIBIT 10.7 HYSEQ, INC.Stock Purchase Agreement • June 12th, 1997 • Hyseq Inc • California
between HYSEQ, INC. and AFFYMETRIX, INC.Settlement Agreement • July 22nd, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
ARCA BIOPHARMA, INC., Issuer AND [TRUSTEE], Trustee FORM OF INDENTURE Dated as of [—], 20 Subordinated Debt SecuritiesIndenture • March 9th, 2011 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of subordinated debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
INDEMNIFICATION AGREEMENTIndemnification Agreement • May 14th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [●], 2024 between Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), and [●] (“Indemnitee”).
HYSEQ, INC.Registration Rights Agreement • June 12th, 1997 • Hyseq Inc • Illinois
Exhibit 8.1 [LETTERHEAD OF LATHAM & WATKINS] December 13, 2002 Hyseq, Inc. 670 Alamanor Avenue Sunnyvale, California 94085 RE: AGREEMENT AND PLAN OF MERGER BY AND AMONG HYSEQ, INC., VERTICAL MERGER CORP., AND VARIAGENICS, INC. DATED AS OF NOVEMBER 9,...Agreement and Plan of Merger • December 13th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances
PRE-FUNDED COMMON STOCK PURCHASE WARRANTWarrant Agreement • June 3rd, 2020 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from ARCA biopharma, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
ARTICLE I. DEFINITIONSSecurities Purchase Agreement • June 14th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
EXHIBIT 4.7 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of April 5, 2002, by and among Hyseq, Inc., a Nevada corporation (the "Company"), and the investors signatory hereto (each a...Registration Rights Agreement • June 14th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
ARCA BIOPHARMA, INC. AND _______________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________Preferred Stock Warrant Agreement • May 7th, 2020 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
ARCA BIOPHARMA, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________Common Stock Warrant Agreement • May 7th, 2020 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
ARCA BIOPHARMA, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFWarrant Agreement • May 7th, 2020 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
EXHIBIT 10.3(a) EMPLOYMENT AGREEMENT -------------------- THIS EMPLOYMENT AGREEMENT ("Agreement"), made and entered into as of the 1st day of August, 1994, by and between HYSEQ, INC., a Nevada corporation (the "Corporation"), and DR. RADOJE T. DRMANAC...Employment Agreement • June 12th, 1997 • Hyseq Inc • Illinois
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 23rd, 2013 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January , 2013, is by and among ARCA biopharma, Inc., a Delaware corporation (the “Company”), and the undersigned buyer ( “Buyer”).
EXHIBIT 10.6 LICENSE AGREEMENT ----------------- THIS LICENSE AGREEMENT (the "Agreement") dated September 25, 1995, between Hyseq Diagnostics Inc., a Nevada corporation with a principal place of business at 670 Almanor, Sunnyvale, California 94086...License Agreement • August 7th, 1997 • Hyseq Inc • In vitro & in vivo diagnostic substances • Pennsylvania
ARTICLE 1. DEFINITIONS -----------Patent License Agreement • August 7th, 1997 • Hyseq Inc • In vitro & in vivo diagnostic substances • Illinois
Exhibit 99.1 VOTING AGREEMENT VOTING AGREEMENT (the "Agreement"), dated as of November 9, 2002, between the undersigned stockholder ("Stockholder") of Hyseq, Inc., a Nevada corporation ("Parent"), and Variagenics, Inc., a Delaware corporation (the...Voting Agreement • November 12th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • Delaware
ARTICLE I. LINE OF CREDITLine of Credit Agreement • April 1st, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
EXHIBIT 10.29 WARRANT PURCHASE AGREEMENT This Warrant Purchase Agreement (the "Agreement") is made as of January 8, 2002 by and between Hyseq, Inc., a Nevada corporation (the "Company"), and Amgen Inc., a Delaware corporation ("Purchaser"). The...Warrant Purchase Agreement • May 15th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
NUVELO, INC. INDENTUREIndenture • July 8th, 2003 • Nuvelo Inc • In vitro & in vivo diagnostic substances • New York
HYSEQ INC. HYSEQ, INC. STOCK OPTION AGREEMENT ----------------------Stock Option Agreement • May 20th, 1998 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
April 11, 2013Placement Agent Agreement • May 24th, 2013 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
ARCA BIOPHARMA, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENTDebt Securities Warrant Agreement • April 4th, 2014 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
UNDERWRITING AGREEMENT DATED FEBRUARY 1, 2005 NUVELO, INC. 8,500,000 Shares Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • February 2nd, 2005 • Nuvelo Inc • In vitro & in vivo diagnostic substances • New York
Nuvelo, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representatives, an aggregate of 8,500,000 shares (the “Firm Shares”) of common stock, $0.001 par value per share (the “Common Stock”), of the Company. In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 1,275,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are hereinafter collectively sometimes referred to as the “Shares.” The Shares are described in the Prospectus which is referred to below.
PLACEMENT AGENCY AGREEMENT January 21, 2014Placement Agency Agreement • February 4th, 2014 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
Introduction. Subject to the terms and conditions herein (this “Agreement”), ARCA biopharma, Inc., a Delaware corporation (the “Company”), proposes to offer and sell registered securities of the Company, including, but not limited to, shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and registered warrants to purchase Common Stock (the “Warrants” and, together with the Shares, and the Common Stock underlying the Warrants, the “Securities”) directly to various investors (each, an “Investor” and, collectively, the “Investors”) through Dawson James Securities, Inc., as placement agent (“Dawson” or the “Placement Agent”).
RECITALSCollaboration and License Agreement • July 22nd, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
EXHIBIT 10.3(b) EMPLOYMENT AGREEMENT -------------------- THIS EMPLOYMENT AGREEMENT ("Agreement"), made and entered into as of the 1st day of August, 1994, by and between HYSEQ, INC., a Nevada corporation (the "Corporation"), and DR. RADOMIR B....Employment Agreement • June 12th, 1997 • Hyseq Inc • Illinois
